A kind of honokiol prodrug and preparation method thereof

By reacting Hematopol with chloromethyl carbonate, the problems of low bioavailability and short half-life of Hematopol were solved, and its bioavailability and half-life were significantly improved. Suitable for tumor treatment, providing better drug choices.

CN118496101BActive Publication Date: 2024-12-06BEIJING JINRUI FOUNDATION PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410565148.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-09
Publication Date
2024-12-06
Estimated Expiration
2044-05-09

AI Technical Summary

Technical Problem

The low bioavailability and short half-life of Magnolia , limit its application range in clinical practice , the improvement effect of existing prodrugs is limited , and new high bioavailability and long half-life prodrugs are needed .

Method used

The compounds are prepared by reacting Hematopol with chloromethyl carbonate under alkaline conditions to form Hematopol methyl carbonate derivatives, which significantly improves their bioavailability and half-life and is used in tumor treatment.

Benefits of technology

It significantly improves the bioavailability and half-life of Magnolia . The released Magnolia , which accumulates and penetrates the disease site more effectively , provides a better choice for Magnolia , and the preparation method is simple and collects. High rate and purity, suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118496101B_ABST
    Figure CN118496101B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of medicine, and specifically relates to a honokiol prodrug and a preparation method thereof. The prodrug not only significantly improves the bioavailability of honokiol, but also significantly prolongs the half-life of honokiol, has good stability in plasma, and the released honokiol is more conducive to accumulation and penetration in the disease site. The drug has excellent comprehensive performance, and provides a new and better choice for honokiol drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to a honokiol prodrug and a preparation method thereof. Background Art

[0002] Honokiol, chemical formula is C 18 H 18 O2, chemical name 3',5-di-2-propenyl-1,1'-biphenyl-2,4'-diol, has obvious and lasting central muscle relaxation, central nervous system inhibition, anti-inflammatory, antibacterial, anti-pathogenic microorganisms, anti-ulcer, antioxidant, anti-aging, anti-tumor, cholesterol lowering and other pharmacological effects, used to treat acute enteritis, bacterial or amoebic dysentery, chronic gastritis, etc. Clinically, it is mainly used to eliminate chest and abdominal fullness, calm the central nervous system, relax athletes' muscles, anti-fungal, anti-ulcer and other drugs. According to existing reports, the medical use of honokiol can also be extended to mental diseases. However, due to its low bioavailability, honokiol needs to be prepared into complex special preparations in order to improve its clinical efficacy during drug development, which has high requirements for the preparation process; at the same time, honokiol has a short half-life and frequent clinical administration, which limits its scope of medical application.

[0003] Prodrug refers to a class of compounds that are inactive or less active in vitro, and release active substances to produce pharmacological effects through one or more steps of enzyme and / or chemical biotransformation in vivo, also known as bioreversible drugs. Prodrug is a very useful drug design method, widely used in the design of various drug molecules. Many drugs are given in the form of prodrugs, and compared with the potential active components, the prodrugs show improved bioavailability, such as improved physicochemical properties, more specifically solubility, active or passive absorption properties or tissue-specific distribution. The properties of the potential active components are usually improved by prodrug residues, and in order to achieve the best action curve, it is necessary to design reasonable prodrug residues and ideal release mechanisms according to the properties, indications, targets and routes of administration of the active components. The prior art has reported the use of honokiol prodrugs to increase the half-life of honokiol, such as the document "Preparation and in vitro and in vivo study of resveratrol nanoparticles and honokiol prodrug nanoparticles" published by Di Jing, which discloses HK-hexanoate prodrugs: HK-caprate ester prodrug: Among them, the half-life of HK (honokiol) converted from HK-caprylate prodrug nanoparticles is 2.97h, which is higher than the half-life of HK in HK nanoparticles (2.18h), but the degree of improvement is limited. It is urgent to develop new honokiol prodrugs to improve the bioavailability and half-life of honokiol. Summary of the invention

[0004] The purpose of the present invention is to provide a honokiol prodrug with high bioavailability and long half-life and a preparation method thereof.

[0005] The present invention provides a compound as shown in formula (I):

[0006]

[0007] In the formula, R1 and R2 are each independently selected from C1 alkyl, C2 alkyl or C3 alkyl.

[0008] Preferably, R1 and R2 are each independently selected from methyl, ethyl or n-propyl.

[0009] Preferably, the compound is:

[0010]

[0011] The present invention also provides a method for preparing the above compound, comprising:

[0012] The compound of formula (I) is prepared by reacting honokiol with chloromethyl carbonate under alkaline conditions.

[0013] Preferably, the chloromethyl carbonate includes chloromethyl methyl carbonate, chloromethyl ethyl carbonate or chloromethyl n-propyl carbonate.

[0014] Preferably, the molar ratio of honokiol, chloromethyl carbonate and base is 1:(2.5-3.0):(3.0-3.5), more preferably 1:2.5:3.0.

[0015] Preferably, the solvent of the reaction includes one or more of N,N-dimethylformamide, dichloromethane, tetrahydrofuran, and 1,4-dioxane, more preferably N,N-dimethylformamide.

[0016] Preferably, the base includes one or more of potassium carbonate, triethylamine, and sodium tert-butoxide, more preferably potassium carbonate.

[0017] Preferably, the reaction temperature is 20°C to 40°C, more preferably 25°C to 35°C, and the reaction time is 3h to 8h, more preferably 3h to 5h.

[0018] The present invention also provides a use of the compound of formula (I) in preparing drugs for treating tumors.

[0019] The tumor includes, but is not limited to, lung cancer, breast cancer, primary brain tumor, metastatic tumor, intracranial abscess, meningioma, melanoma, colon cancer, adenocarcinoma, liver cancer or glioma.

[0020] Unless otherwise specified in the present invention, bioavailability refers to absolute bioavailability.

[0021] The beneficial effects of the present invention are as follows:

[0022] The compound of the present invention, as a prodrug of honokiol, not only significantly improves the bioavailability of honokiol, but also significantly prolongs the half-life of honokiol, has good stability in plasma, and the released honokiol is more conducive to accumulation and penetration in the disease site. The comprehensive drug performance is excellent, providing a new and better choice for honokiol drugs.

[0023] The preparation method of the compound of the invention is simple, has high yield and purity, and is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The figure is a reaction scheme of the compound of the present invention (honokiol methyl carbonate derivative).

[0025] Figure 2 This is the HPLC detection chart of the magnolol methyl carbonate derivative prepared in Example 2.

[0026] Figure 3 The methyl carbonate derivative of honokiol prepared in Example 2 1 HNMR detection diagram.

[0027] Figure 4 The methyl carbonate derivative of honokiol prepared in Example 2 13 CNMR detection image. DETAILED DESCRIPTION

[0028] The present invention is described in more detail below by way of examples. The following examples are provided for the purpose of illustrating the present invention by way of example only and are not intended to limit the scope of the present invention.

[0029] In the examples of the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art; in the examples of the present invention, unless otherwise specified, the technical means used are conventional means well known to those skilled in the art.

[0030] The present invention uses honokiol and chloromethyl methyl carbonate to react and purify to prepare honokiol methyl carbonate derivatives, the reaction formula is as follows: Figure 1 shown.

[0031] The purity of the present invention is obtained by HPLC testing.

[0032] The BALB / c male mice involved in the embodiments of the present invention were sourced from Chengdu Dashuo Experimental Animal Co., Ltd., and honokiol was sourced from Chengdu Jinrui Jiye Biotechnology Co., Ltd.

[0033] Example 1

[0034] This embodiment provides a method for preparing a methyl carbonate derivative of honokiol, comprising the following steps:

[0035] 5.0g (18.77mmol) of honokiol was added into 50ml N,N-dimethylformamide, stirred to dissolve, 7.8g (56.31mmol) of potassium carbonate was added, 7.0g (56.31mmol) of chloromethyl methyl carbonate was added dropwise, the temperature was raised to 25-35℃ for reaction for 3h, TLC monitored the reaction of the raw materials, 150ml of water was added dropwise to quench the reaction, the product was extracted with dichloromethane (20ml / time * 3 times), washed with 20ml of water, washed with 20ml of saturated sodium bicarbonate aqueous solution, washed with 20ml of saturated brine, and the organic phase was dried over sodium sulfate and concentrated to obtain 6.3g of colorless oil. Purity: 98.33%, yield: 87.74%.

[0036] Example 2

[0037] This embodiment provides a method for preparing a methyl carbonate derivative of honokiol, comprising the following steps:

[0038] Put 100.0g (375.46mmol) of honokiol into 1000ml N,N-dimethylformamide, stir to dissolve, add 156.2g (1.13mol) of potassium carbonate, add 116.9g (938.65mmol) of chloromethyl methyl carbonate dropwise, control the temperature at 25-40℃ and react for 5h, monitor the reaction of the raw materials by TLC, add 3.0L of water dropwise to quench the reaction, extract the product with dichloromethane (400ml / time * 3 times), combine the organic phases, wash with 400ml of water, wash with 400ml of saturated sodium bicarbonate aqueous solution, wash with 400ml of saturated brine, dry with sodium sulfate and concentrate to obtain 126.3g of colorless oil. Purity measured by HPLC: 98.54%, such as Figure 2 As shown; yield: 87.96%.

[0039] like Figure 3 As shown, 1 H NMR (400MHz, CDCl3): 3.42-3.44(2H), 3.46-3.48(2H), 3.76(3H), 3.95(3H), 5.11-5.19(4H), 5.92-6.07(2H), 7.17-7.26(4H), 7.35-7.38(2H).

[0040] like Figure 4 As shown, 13C NMR (400MHz, CDCl3): 34.44, 39.63, 55.37, 55.51, 116.42, 116.50, 121.96, 122.34, 128.18, 128.90, 131.03, 131.06, 131.85, 133.57, 135.40, 135.63, 136.92, 138.58, 146.48, 148.87, 154.05, 154.16.

[0041] Example 3

[0042] This embodiment provides a method for preparing a methyl carbonate derivative of honokiol, comprising the following steps:

[0043] 5.0g (18.77mmol) of honokiol was added into 50ml of dichloromethane, stirred to dissolve, 7.8g (56.31mmol) of potassium carbonate was added, 7.0g (56.31mmol) of chloromethyl methyl carbonate was added dropwise, the temperature was raised to 25-35℃ for reaction for 5h, TLC monitored the reaction of the raw materials, 150ml of water was added dropwise to quench the reaction, and then the liquid was separated, the aqueous phase was extracted with dichloromethane (20ml / time * 2 times), washed with 20ml of water, washed with 20ml of saturated sodium bicarbonate aqueous solution, washed with 20ml of saturated brine, and the organic phase was dried over sodium sulfate and concentrated to obtain 5.5g of colorless oil. Purity: 98.03%, yield: 76.61%.

[0044] Example 4

[0045] The pharmacokinetics of the methyl carbonate derivative of honokiol (the methyl carbonate derivative of honokiol prepared in Example 1) were investigated by intravenous administration (14.358 mg / kg) (converted to the same molar number of honokiol 10 mg / kg) and oral administration (14.358 mg / kg) (converted to the same molar number of honokiol 10 mg / kg) to BALB / c mice.

[0046] BALB / c mice were intravenously administered (10 mg kg -1 ) and oral administration (10 mg kg -1 ) to investigate the pharmacokinetics of magnolia officinalis.

[0047] Weigh about 5 mg of honokiol carbonate methyl ester derivative, add 30 μL DMSO to dissolve, and then add sodium chloride solution for injection to make 1 mg mL -1 A solution of the compound is prepared for administration.

[0048] Weigh about 3 mg of honokiol, add 30 μL of DMSO to dissolve, and then add sodium chloride solution for injection to make 1 mg mL -1The HK compound solution is prepared for administration.

[0049] Weigh about 10 mg of HK reference substance and dilute to 1 mg ml with methanol. -1 Obtain the magnolol stock solution.

[0050] The specific experimental process is as follows:

[0051] 1. Sample collection

[0052] Twelve BALB / c male mice (weighing about 25 g) were divided into four groups, with 3 mice in each group. Group 1: intravenous administration of magnolol methyl carbonate derivatives, Group 2: oral administration of magnolol methyl carbonate derivatives, Group 3: intravenous administration of magnolol, Group 4: oral administration of magnolol, about 0.05 mL of blood was collected at 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h and 24h after administration, the collected blood was centrifuged at 3500rpm for 15min, the supernatant plasma was collected, and frozen at -40℃ for testing.

[0053] 2. Sample determination

[0054] 1. Preparation of standard solution

[0055] Use a pipette to accurately draw a certain amount of honokiol stock solution (1 mg ml -1 ), diluted with methanol to concentrations of 10, 30, 100, 300, 1000, and 3000 ng ml -1 Mixed solution of honokiol (HK) standard.

[0056] 2. Preparation of mobile phase and needle washing solution

[0057] Phase A: 0.1% formic acid in water (v / v),

[0058] Phase B: acetonitrile,

[0059] Needle washing solution: 90% methanol water.

[0060] 3. Establishment of standard curve

[0061] Take 9 μL of blank plasma in each EP tube, add 1 μL of the mixed solution of honokiol standard of each concentration under the above "Preparation of standard solution", vortex to mix, add 40 μL of acetonitrile to precipitate protein, vortex for 30 seconds, centrifuge at 13000 rpm for 15 minutes, take the supernatant and put it into the injection bottle for testing. The theoretical concentrations of honokiol are 1, 3, 10, 30, 100, 300 ng·ml -1 .

[0062] 4. Preparation of Plasma Samples

[0063] After the collected plasma samples were thawed at room temperature, they were vortexed and mixed evenly. 10 μL of plasma was taken into each EP tube, 40 μL of acetonitrile was added to precipitate protein, vortexed for 30 seconds, centrifuged at 13000 rpm for 15 minutes, and the supernatant was taken and placed in a sample injection bottle for testing.

[0064] 5. Sample measurement method

[0065] 5.1 Liquid phase conditions

[0066] Flow rate: 0.6 mL min -1 ; Sample room temperature: 15℃; Column temperature: 35℃; Equilibration time: 1min, injection: 1uL. Chromatographic column: ACQUITY BEH C 18 1.7um, 2.1×100mm column, gradient elution as shown in Table 1.

[0067] Table 1. Liquid phase conditions

[0068] Time (min) Flow rate (ml / min) 0.1% formic acid water (%) Acetonitrile (%) 0 0.6 40 60 0.8 0.6 10 90 2.0 0.6 10 90

[0069] 5.2 Mass spectrometry parameters

[0070] Electrospray ionization (ESI) mode was used, and the detection ions were negative ions; the capillary voltage was -4.5 kV, the ion source temperature was 500 °C, and the declustering voltage (DP) was -100 V. HK was determined in multi-stage reaction monitoring mode (MRM) mode, and the corresponding monitoring ion pairs and collision energies are shown in Table 2.

[0071] Table 2. Mass spectrometry parameters of HK

[0072] Analytes Precursor ion Product ions Dwell time Collision Energy HK 265.1 223.0 0.1S -45ev

[0073] 6. Experimental Results

[0074] The measured data of the concentration of magnolia officinalis in plasma and time (ct) after intravenous and oral administration of magnolia officinalis carbonate methyl ester derivatives are shown in Table 3.

[0075] Table 3. CT data of honokiol in plasma after administration of honokiol methyl carbonate derivatives

[0076]

[0077] The results of the data of oral and intravenous administration of magnolol carbonate methyl ester derivatives processed by DAS2.0 software are shown in Tables 4 and 5, and the explanations of terms are shown in Table 6.

[0078] Table 4 Results of intragastric administration of magnolol methyl carbonate derivatives

[0079] parameter unit 4# Mouse 5# Mouse 6# Mouse Mean SD AUC(0-t) ug / L*h 37.24 38.73 31.44 35.80 3.85 AUC(0-∞) ug / L*h 41.91 46.14 106.34 64.80 36.04 AUMC(0-t) 319.19 369.89 316.59 335.22 30.05 AUMC(0-∞) 478.57 634.48 801.75 638.27 161.63 MRT(0-t) h 8.57 9.55 10.07 9.40 0.76 MRT(0-∞) h 11.42 13.75 7.54 10.90 3.14 VRT(0-t) h^2 34.64 38.08 46.54 39.75 6.12 VRT(0-∞) h^2 104.26 140.16 203.58 149.34 50.29 t1 / 2z h 6.70 7.64 11.55 8.63 2.57 Tmax h 0.25 8.00 0.25 2.83 4.47 CL L / h / kg 238.59 216.75 94.04 183.13 77.92 V L / kg 2306.55 2389.24 1567.08 2087.62 452.69 Cmax ug / L 4.20 3.30 2.67 3.39 0.77

[0080] Table 5 Results of intravenous administration of magnolol methyl carbonate derivatives

[0081] parameter unit 1# Mouse 2# Mouse 3# Mouse Mean SD AUC(0-t) ug / L*h 255.16 244.46 287.74 262.46 22.54 AUC(0-∞) ug / L*h 262.18 249.50 300.86 270.85 26.76 AUMC(0-t) 410.59 344.55 622.42 459.18 145.17 AUMC(0-∞) 675.85 550.13 1111.67 779.21 294.69 MRT(0-t) h 1.61 1.41 2.16 1.73 0.39 MRT(0-∞) h 2.58 2.21 3.70 2.83 0.78 VRT(0-t) h^2 12.96 10.72 20.46 14.71 5.10 VRT(0-∞) h^2 51.96 46.30 79.40 59.22 17.71 t1 / 2z h 9.62 11.33 9.39 10.11 1.06 Tmax h 0.25 0.08 0.08 0.14 0.10 CL L / h / kg 38.14 40.08 33.24 37.15 3.53 V L / kg 529.38 655.40 450.40 545.06 103.39 Cmax ug / L 310.49 365.03 451.18 375.57 70.93

[0082] Table 6 Name Explanation

[0083]

[0084] The data of measured plasma concentration of magnolia officinalis and time (ct) after intravenous and oral administration of magnolia officinalis are shown in Table 7.

[0085] Table 7 CT data of honokiol in plasma after administration of honokiol

[0086]

[0087] The results of processing the data of oral and intravenous administration of honokiol using DAS2.0 software are shown in Tables 8 and 9, and the name explanations are shown in Table 6.

[0088] Table 8 Results of intragastric administration of magnolol

[0089] parameter unit 7# Mouse 8# Mouse 9# Mouse Mean SD AUC(0-t) ug / L*h 38.20 24.00 55.80 39.33 15.93 AUC(0-∞) ug / L*h 52.07 25.98 60.42 46.16 17.97 AUMC(0-t) 93.74 96.99 200.89 130.54 60.95 AUMC(0-∞) 390.80 180.57 263.87 278.41 105.87 MRT(0-t) h 2.45 4.04 3.60 3.37 0.82 MRT(0-∞) h 7.51 6.95 4.37 6.27 1.68 VRT(0-t) h^2 8.61 8.68 8.52 8.60 0.08 VRT(0-∞) h^2 105.36 20.32 14.79 46.82 50.77 t1 / 2z h 7.51 2.30 1.96 3.92 3.11 Tmax h 0.08 0.08 0.25 0.14 0.10 CL L / h / kg 192.04 384.88 165.51 247.48 119.74 V L / kg 2079.79 1278.68 468.19 1275.56 805.80 Cmax ug / L 43.80 8.56 26.18 26.18 17.62

[0090] Table 9 Results of intravenous administration of honokiol

[0091]

[0092]

[0093] Result analysis:

[0094] According to the 2005 edition of CDE's "Technical Guidelines for Human Bioavailability and Bioequivalence Studies of Chemical Drug Preparations", the formula for the absolute bioavailability (F) value is:

[0095] F=AUCpo·Div / AUCiv·Dpo×100% (AUCpo: area under the curve when the drug is administered by intravenous administration, AUCiv: area under the curve when the drug is administered by intravenous administration, Div: intravenous administration concentration, Dpo: intravenous administration concentration).

[0096] The F of the methyl honokiol carbonate derivative is (35.80*10) / (262.46*10)*100%=13.64%.

[0097] F of honokiol = (39.33*10) / (2451.936*10)*100% = 1.6%.

[0098] The comparison of bioavailability and half-life of honokiol methyl carbonate derivatives and honokiol is shown in Table 10.

[0099] Table 10 Comparison of bioavailability and half-life

[0100]

[0101] As shown in Table 10, the bioavailability of honokiol methyl carbonate derivatives is stronger than that of honokiol, and its half-life under different administration conditions is also stronger than that of honokiol.

[0102] Example 5

[0103] The compounds of the present invention not only significantly improve the bioavailability and half-life of honokiol, but the inventors also unexpectedly found that the compounds of the present invention (especially the honokiol methyl carbonate derivatives in Example 1) are better than other derivatives (such as honokiol diacetate derivatives) in terms of ) has excellent plasma stability. The specific experimental process is as follows:

[0104] 1. Preparation method of honokiol diacetate derivative

[0105] Synthesis route:

[0106] Preparation process: Take magnolol (5.0g), add 25ml of dichloromethane to dissolve, add 5.7g (3.0eq) of triethylamine, control the temperature at about 0°C and add 4.8g (2.5eq) of acetic anhydride dropwise, react at 25°C for 4h, the raw materials react completely, add 20ml of water to quench the reaction, separate the liquids, add 25ml of dichloromethane to the aqueous phase to extract the product, separate the liquids, wash the combined organic phases with 20ml of saturated sodium bicarbonate aqueous solution, wash with 20ml of saturated brine, dry the organic phase over sodium sulfate, and concentrate to obtain 5.8g of magnolol diacetate derivative.

[0107] 2. Experimental procedures for determining stability in rat plasma

[0108] (1) Method parameters

[0109] Octadecylsilane bonded silica gel was used as filler (chromatographic column, Phenomenex Gemini C18, 4.6 mm × 150 mm, 5 μm or chromatographic column of equivalent performance); 10% acetonitrile aqueous solution containing 0.1% formic acid was used as mobile phase A, acetonitrile containing 0.05% formic acid was used as mobile phase B, and linear gradient elution was performed according to Table 11; the flow rate was 1.0 ml per minute; the column temperature was 30°C; the detection wavelength was 254 nm; and the injection volume was 10 μl.

[0110] Table 11 Linear gradient elution conditions

[0111] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 40 60 5 40 60 6 5 95 10 5 95 11 40 60 15 40 60

[0112] Note: The method parameters are aimed at separating the main components of magnolol and magnolol derivatives.

[0113] (2) Test process

[0114] Study on degradation rate in the incubation system of 0.5ml PBS (phosphate buffered saline, pH 6.8) + 0.1ml rat plasma:

[0115] Test sample stock solution: Take the product, weigh accurately, add DMSO to dissolve and quantitatively dilute to a solution containing approximately 2 mg per 1 ml.

[0116] Test solution: Add 0.5 ml of PBS (pH 6.8) solution and 0.1 ml of rat plasma to the reaction system, keep warm at 37°C for 15 min (or ice bath), then add 0.5 ml of test stock solution. After a period of reaction, add 3.9 ml of acetonitrile, vortex and mix for 30 seconds to precipitate protein, centrifuge at 12000 rpm for 10 min, take the supernatant, inject into the injection bottle, and determine by HPLC.

[0117] 3. Test results

[0118] The test results of the compounds in 0.1 ml rat plasma incubation system at 37°C are shown in Table 12.

[0119] Table 12 Test results of compounds in rat plasma incubation system at 37°C

[0120]

[0121] 4. Conclusion

[0122] After the magnolol diacetate derivative was reacted in a 0.1 ml rat plasma incubation system for 5 minutes, the main component disappeared and was basically converted into magnolol in 30 minutes; after the magnolol methyl carbonate derivative was reacted in a 0.1 ml rat plasma incubation system for 1 hour, the main component was not detected and was basically converted into magnolol in 6 hours, indicating that the magnolol carbonate derivative was more stable than the magnolol diacetate derivative in the rat plasma system, and the magnolol methyl carbonate derivative had a higher content of magnolol released by enzymatic hydrolysis.

[0123] It is necessary to point out that the above embodiments are limited to further elaboration and explanation of the technical solution of the present invention, and are not further limitations of the technical solution of the present invention. The method of the present invention is only a preferred implementation scheme, and is not used to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A compound represented by formula (I): In the formula, R1 and R2 are each independently selected from C1 alkyl, C2 alkyl or C3 alkyl.

2. The compound according to claim 1, It is characterized in that The R1 and R2 are each independently selected from methyl, ethyl or n-propyl.

3. The compound according to claim 2, It is characterized in that The compound is:

4. A method for preparing the compound according to any one of claims 1 to 3, include: The compound of formula (I) is prepared by reacting honokiol with chloromethyl carbonate under alkaline conditions.

5. The preparation method according to claim 4, It is characterized in that The chloromethyl carbonate includes chloromethyl methyl carbonate, chloromethyl ethyl carbonate or chloromethyl n-propyl carbonate.

6. The preparation method according to claim 4, It is characterized in that The molar ratio of honokiol, chloromethyl carbonate and base is 1:(2.5-3.0):(3.0-3.5).

7. The preparation method according to claim 4, It is characterized in that The solvent for the reaction includes one or more of N,N-dimethylformamide, dichloromethane, tetrahydrofuran and 1,4-dioxane.

8. The preparation method according to claim 4, It is characterized in that The base includes one or more of potassium carbonate, triethylamine and sodium tert-butoxide.

9. The preparation method according to claim 4, It is characterized in that The reaction temperature is 20°C to 40°C, and the reaction time is 3h to 8h.

10. Use of a compound of formula (I) as claimed in any one of claims 1 to 3 in the preparation of a drug for treating tumors.